Our results demonstrated that atovaquone treatment resulted in 13% and 40% reduction of TGF-β and IL-10 levels, respectively, indicating a reduction of immunosuppression in the tumor microenvironment (Figure 4A,B). The gene discussed is TGFB1; the disease is neoplasm.